{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:53:32Z","timestamp":1789977212999,"version":"4.0.1"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":8377,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1990,4]]},"abstract":"<jats:p>Binding of drugs can vary considerably. Therefore, binding of the calcium antagonist diltiazem was studied in protein solutions and in serum of healthy persons, patients with renal failure, patients with cirrhosis, patients with rheumatoid arthritis, patients with myocardial infarction, and intensive care patients. The effect of in vitro addition of some cardiovascular drugs (lidocaine, disopyramide, quinidine, and bupivacaine) on the binding of diltiazem in serum of healthy volunteers was also investigated. Diltiazem is bound as well to \u03b1<jats:sub>1<\/jats:sub>\u2010acid glycoprotein (AAG) as to albumin. In patients with renal failure, myocardial infarction, and rheumatoid arthritis and in intensive care patients, AAG concentrations are increased, and in the patients with myocardial infarction an increased binding of diltiazem is found. In patients with cirrhosis, AAG concentrations and diltiazem binding are decreased. In vitro addition of lidocaine, disopyramide, bupivacaine, or quinidine in concentrations between 5 and 100 \u03bcg\/mL, before dialysis, decreases the binding of diltiazem; the displacing effect is most pronounced with bupivacaine.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1990.tb03599.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T21:34:22Z","timestamp":1362778462000},"page":"311-317","source":"Crossref","is-referenced-by-count":12,"title":["Binding of Diltiazem to Albumin, \u03b1<sub>1<\/sub>\u2010Acid Glycoprotein and to Serum in Man"],"prefix":"10.1002","volume":"30","author":[{"given":"F. M.","family":"Belpaire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Bogaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0773.1985.tb03570.x","article-title":"Pharmacokinetics of diltiazem and other calcium entry blockers","volume":"57","author":"Hermann P","year":"1985","journal-title":"Acta Pharmacol Toxicol"},{"key":"e_1_2_1_3_2","first-page":"266","article-title":"Diltiazem binding to human serum proteins","volume":"35","author":"Pieper J","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-178-2-RC2"},{"key":"e_1_2_1_5_2","first-page":"1244","article-title":"Metabolic fate of diltiazem. Distribution, excretion and protein binding in rat and dog","volume":"37","author":"Nakamura S","year":"1987","journal-title":"Drug Res"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(85)90707-5"},{"key":"e_1_2_1_7_2","first-page":"754","article-title":"Interaction between human serum albumin and \u03b11\u2010acid glycoprotein in the binding of lidocaine to purified protein fractions and sera","volume":"239","author":"Kraus E","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(67)90297-7"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb1978.4.879"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(71)90365-2"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1982.tb02163.x"},{"issue":"2","key":"e_1_2_1_12_2","first-page":"1","article-title":"Binding of erythromycin base to human plasma proteins","volume":"8","author":"Prandotta J","year":"1980","journal-title":"J Int Med Res"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197812282992604"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561361"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02525.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb05260.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-5-701"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.184"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00545224"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1990.tb03599.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1990.tb03599.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T20:06:01Z","timestamp":1698005161000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1990.tb03599.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1990,4]]}},"alternative-id":["10.1002\/j.1552-4604.1990.tb03599.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1990.tb03599.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,4]]}}}